| scholarly article | Q13442814 |
| P50 | author | Hélène François | Q73850020 |
| Maxime Touzot | Q57452171 | ||
| P2093 | author name string | Antoine Durrbach | |
| Erika Nnang Obada | |||
| Severine Beaudreuil | |||
| P2860 | cites work | Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype | Q82732283 |
| Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA) | Q83101436 | ||
| Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection | Q84275781 | ||
| Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation | Q84420087 | ||
| Novel small interfering RNA-containing solution protecting donor organs in heart transplantation | Q84529425 | ||
| The value of C4d deposit in post liver transplant liver biopsies | Q84969873 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant | Q85570146 | ||
| The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients | Q85963365 | ||
| Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin | Q59655028 | ||
| Induction of xenograft accommodation by modulation of elicited antibody responses1 2 | Q64378559 | ||
| The effect of soluble complement receptor type 1 on hyperacute allograft rejection | Q67898797 | ||
| Prognosis of acute tubular necrosis: an extended prospectively contrasted study | Q70592766 | ||
| Localization of the complement regulatory proteins in the normal human kidney | Q71651834 | ||
| Expression and tissue localization of donor-specific complement C3 synthesized in human renal allografts | Q72209813 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies | Q73100253 | ||
| Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells | Q73449844 | ||
| Expression of tissue factor and tissue factor pathway inhibitor in porcine endothelium in response to natural antibody and complement | Q73668433 | ||
| Use of C4d as a diagnostic adjunct in lung allograft biopsies | Q73810381 | ||
| Complement regulatory proteins in glomerular diseases | Q77650589 | ||
| Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction | Q80140686 | ||
| Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection | Q80977850 | ||
| C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients | Q81180697 | ||
| Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation | Q81317216 | ||
| A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation | Q82055056 | ||
| Local extravascular pool of C3 is a determinant of postischemic acute renal failure | Q82436381 | ||
| Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage | Q82699554 | ||
| Structures of C3b in complex with factors B and D give insight into complement convertase formation | Q24601226 | ||
| Expression of complement components differs between kidney allografts from living and deceased donors | Q24654702 | ||
| Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria | Q28256613 | ||
| C3d of complement as a molecular adjuvant: bridging innate and acquired immunity | Q28272810 | ||
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes | Q28610983 | ||
| Complement: a key system for immune surveillance and homeostasis | Q29615484 | ||
| Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies | Q33403607 | ||
| Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports | Q33404327 | ||
| Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome | Q33408211 | ||
| Complement evasion by human pathogens | Q33623972 | ||
| Review: Complement and its regulatory proteins in kidney diseases | Q33647738 | ||
| Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage | Q33745120 | ||
| Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells. | Q34086998 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Accommodation: preventing injury in transplantation and disease | Q34315248 | ||
| Genotypic diversity of complement component C4 does not predict kidney transplant outcome | Q34534928 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. | Q34659840 | ||
| Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells | Q34760201 | ||
| C5a-induced gene expression in human umbilical vein endothelial cells | Q35094695 | ||
| Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice | Q35655757 | ||
| Complement-induced impairment of the innate immune system during sepsis | Q35850641 | ||
| The complement system in regulation of adaptive immunity | Q35904390 | ||
| The role of complement in inflammatory diseases from behind the scenes into the spotlight | Q35963146 | ||
| C3a and C5a promote renal ischemia-reperfusion injury | Q36200905 | ||
| Identification of the target self-antigens in reperfusion injury | Q36227933 | ||
| Complement-mediated regulation of tissue factor activity in endothelium | Q36365648 | ||
| Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement | Q36366602 | ||
| Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner | Q36584507 | ||
| Targeting complement component 5a promotes vascular integrity and limits airway remodeling | Q36762599 | ||
| A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody | Q36887068 | ||
| Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 | ||
| Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection | Q37106399 | ||
| The alternative complement pathway revisited | Q37141297 | ||
| The critical role of plasmapheresis in ABO-incompatible renal transplantation | Q37227538 | ||
| Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin | Q37430921 | ||
| Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways | Q37596125 | ||
| C3 glomerulopathy: a new classification | Q37770399 | ||
| The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera | Q38036750 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 | ||
| The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury | Q38782859 | ||
| Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates | Q39718995 | ||
| High levels of complement C3a receptor in the glomeruli in lupus nephritis | Q40138591 | ||
| Differential expression of complement C3 and C4 in the human kidney | Q40305030 | ||
| Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis | Q41018168 | ||
| Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. | Q41889471 | ||
| Upregulation of CD59: potential mechanism of accommodation in a large animal model | Q42611073 | ||
| Expression of the decay-accelerating factor (CD55) in renal transplants--a possible prediction marker of allograft survival | Q43288515 | ||
| HLA antibody specification using single-antigen beads--a technical solution for the prozone effect | Q43914521 | ||
| Critical protection from renal ischemia reperfusion injury by CD55 and CD59. | Q44788674 | ||
| Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells | Q45050747 | ||
| Five-year outcomes in living donor kidney transplants with a positive crossmatch. | Q45351621 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors | Q46100656 | ||
| C3 polymorphisms and allograft outcome in renal transplantation | Q46107496 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Kidney allograft survival after acute rejection, the value of follow-up biopsies | Q46211382 | ||
| Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome | Q46322442 | ||
| Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis | Q46610901 | ||
| Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies | Q46900323 | ||
| Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports | Q47845812 | ||
| Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. | Q48024813 | ||
| Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys | Q48771751 | ||
| ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. | Q50579449 | ||
| Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. | Q51333222 | ||
| NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. | Q51676450 | ||
| The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. | Q51738133 | ||
| Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. | Q53181446 | ||
| Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. | Q53475097 | ||
| Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. | Q53659700 | ||
| Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. | Q53965909 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H | Q57089510 | ||
| Local synthesis of complement component C3 regulates acute renal transplant rejection | Q57369617 | ||
| P433 | issue | 3 | |
| P921 | main subject | organ transplantation | Q69253852 |
| P304 | page(s) | 119-125 | |
| P577 | publication date | 2014-03-12 | |
| P1433 | published in | Transplantation Reviews | Q15749559 |
| P1476 | title | Complement modulation in solid-organ transplantation | |
| P478 | volume | 28 |
| Q36302476 | An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA |
| Q37441785 | Antibody-mediated Rejection in Lung Transplantation |
| Q54967868 | Association Between Promoter Polymorphisms in CD46 and CD59 in Kidney Donors and Transplant Outcome. |
| Q35236103 | Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention |
| Q38914719 | Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. |
| Q37634944 | Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q93345812 | iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers in serum of acute cellular rejection after liver transplantation |
Search more.